Literature DB >> 29287903

Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.

Fadi Nasr1, Elie El Rassy2, Georgina Maalouf3, Carine Azar4, Fadi Haddad3, Jeanine Helou4, Caroline Robert5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29287903     DOI： 10.1016/j.ejca.2017.11.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  11 in total

1.  Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.

Authors:  Charlée Nardin; Sophie Borot; Marie-Astride Beaudoin; Françoise Cattin; Eve Puzenat; Anne-Sophie Gauthier; Franck Schillo; Christophe Borg; François Aubin
Journal:  Invest New Drugs       Date:  2018-08-25       Impact factor: 3.850

2.  Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.

Authors:  Ranjan Pathak; Anjan Katel; Erminia Massarelli; Victoria M Villaflor; Virginia Sun; Ravi Salgia
Journal:  Oncologist       Date:  2021-08-25

Review 3.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

4.  Successful Therapy for Myocarditis Concomitant With Complete Heart Block After Pembrolizumab Treatment for Head and Neck Squamous Cell Carcinoma: A Case Report With Literature Review.

Authors:  Lina Su; Chuanfen Liu; Wenjie Wu; Yuxia Cui; Manyan Wu; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2022-05-12

5.  Third Cranial Nerve Palsy after Monoclonal Antibody Therapy for Lung Cancer: A Case Report.

Authors:  Paolo Missori; Angela Ambrosone; Leonardo Cristofani; Francesco Fattapposta; Antonio Currà
Journal:  Case Rep Ophthalmol       Date:  2022-04-21

6.  Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.

Authors:  Tomas G Neilan; Mace L Rothenberg; Laleh Amiri-Kordestani; Ryan J Sullivan; Richard M Steingart; William Gregory; Subramanian Hariharan; Tarek A Hammad; JoAnn Lindenfeld; Martin J Murphy; Javid J Moslehi
Journal:  Oncologist       Date:  2018-05-25

Review 7.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

8.  Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung.

Authors:  Xiaohong Xie; Fei Wang; Yinyin Qin; Xinqing Lin; Zhanhong Xie; Ming Liu; Ming Ouyang; Bihui Luo; Yingying Gu; Shiyue Li; Dejian Gu; Rongrong Chen; Chengzhi Zhou
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

9.  Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.

Authors:  Naoki Hamada; Ayaka Maeda; Kaoru Takase-Minegishi; Yohei Kirino; Yumiko Sugiyama; Ho Namkoong; Nobuyuki Horita; Ryusuke Yoshimi; Hideaki Nakajima
Journal:  Front Immunol       Date:  2021-12-06       Impact factor: 7.561

Review 10.  Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.

Authors:  Emma Matzen; Lars Erik Bartels; Brian Løgstrup; Stine Horskær; Christina Stilling; Frede Donskov
Journal:  Cardiooncology       Date:  2021-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.